Metabolic Health, Menopause, Longevity & Fitness

How to read this section

These are the four areas that drive most peptide searches. What follows is physiological and evidence context — the mechanisms involved, what has been demonstrated in humans, and where the literature is thin. It deliberately contains no product recommendations and no promises about outcomes, because the honest answer in every one of these areas is that the foundational interventions have far stronger evidence than any peptide.

Metabolic health

• Incretin biology (GLP-1, GIP, glucagon) is the best-evidenced area in peptide medicine, with large Phase III trials and approved products for type 2 diabetes and obesity.
• Documented effects include reduced appetite, delayed gastric emptying, improved glycemic control, and clinically meaningful weight reduction — alongside a well-characterized side effect profile.
• Muscle mass preservation during rapid weight loss depends on adequate protein intake and resistance training; this is a nutrition and training question, not a peptide question.
• Weight regain after discontinuation is common and expected, which makes the long-term plan more important than the starting protocol.

Menopause and perimenopause

• Vasomotor symptoms, sleep disruption, mood change, bone density loss, and shifts in body composition are driven primarily by declining estradiol and progesterone.
• The interventions with the strongest evidence are hormone therapy where appropriate, resistance training, adequate protein and calcium, vitamin D status, and sleep management.
• Peptide evidence specific to menopausal symptoms is limited. Compounds studied for bone (teriparatide, abaloparatide) have real approved indications and real contraindications, and belong in a prescriber conversation.
• Cardiovascular and bone risk both change at menopause, which makes baseline assessment more valuable than any single agent.

Longevity

• Almost all peptide longevity data is pre-clinical. Rodent lifespan extension has a poor track record of translating to humans.
• Mechanistic targets under study include mitochondrial function, senescent cell burden, telomere biology, autophagy, and inflammatory signaling.
• Biological age tests and epigenetic clocks are research tools with meaningful measurement variability; a change in a clock reading is not a demonstrated change in lifespan.
• The interventions with human outcome data remain unglamorous: not smoking, cardiorespiratory fitness, strength, sleep, diet quality, blood pressure and lipid control, and social connection.

Fitness and recovery

• Growth hormone secretagogues raise GH and IGF-1; demonstrating that they improve strength, body composition, or injury recovery in healthy trained adults is a separate and much weaker evidentiary claim.
• Tissue-repair compounds are dominated by animal and case-report data. Enthusiasm considerably outruns controlled human evidence.
• Many performance compounds are prohibited under WADA and most sport governing bodies. Competing athletes should verify status before use.
• Progressive overload, protein intake, sleep, and load management remain the highest-yield levers for every goal in this category.